Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Innate Immunity in Cancer Biology and Therapy

The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Exploiting innate immunity for cancer immunotherapy

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Harnessing innate immune pathways for therapeutic advancement in cancer

Target tumor microenvironment by innate T cells

Role of tumor microenvironment in cancer progression and therapeutic strategy

Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Decoding the Interplay: Exploring Immunotherapy Resistance in the Tumor Microenvironment

New horizons in tumor microenvironment biology: challenges and opportunities

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

Targeting the Innate Immune System with Nanoparticles for Cancer Immunotherapy

Targeting Innate Immunity in Cancer Therapy

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Deciphering Innate Immune Cell-Tumor Microenvironment Crosstalk at a Single-Cell Level